Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06282094 · ClinicalTrials.gov registry record

ViSiGi LUX Bariatric Sizing and Calibration System

A clinical trial of Bariatric Surgery Candidate, sponsored by Boehringer Labs.

Recruiting
Registry status
30
Enrollment target
1
Study location

NCT06282094: Recruiting study of Bariatric Surgery Candidate, sponsored by Boehringer Labs.

NCT06282094 is a study of Bariatric Surgery Candidate that is actively recruiting participants, run by Boehringer Labs. The registered enrollment target is 30 participants, below the 112-participant average among 28 other Bariatric Surgery Candidate trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06282094, a study of Bariatric Surgery Candidate, is actively recruiting participants, sponsored by Boehringer Labs.

RECRUITING
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

This study investigates the new ViSiGi LUX.

Study Locations (1)

Pennsylvania

  • WellSpan - York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-01-26
Est. Completion 2024-03
Boehringer Labs

3 total trials

What NCT06282094 shows while recruiting

NCT06282094 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 112-participant average among 28 other Bariatric Surgery Candidate trials with a reported enrollment target (73% lower).

The record links to 1 condition, with Bariatric Surgery Candidate appearing as the primary indexed condition, and to 0 interventions.

NCT06282094 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06282094 about?

NCT06282094 is a clinical study titled "ViSiGi LUX Bariatric Sizing and Calibration System". This study investigates the new ViSiGi LUX.

What is the current status of trial NCT06282094?

This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2024-01-26. Estimated completion is 2024-03.

What conditions does trial NCT06282094 study?

This clinical trial studies the following conditions: Bariatric Surgery Candidate.

Who is sponsoring clinical trial NCT06282094?

This trial is sponsored by Boehringer Labs, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06282094 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bariatric Surgery Candidate

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06282094's enrollment target sits among peer trials

30 20th of 28 higher than 6 of 28 other Bariatric Surgery Candidate trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bariatric Surgery Candidate trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06282094, the US trial registry maintained by the National Library of Medicine. NCT06282094 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.